OmniAb (OABI) Q4 2025 Earnings Call Transcript

OmniAb reported FY2025 revenue of $18.7M (down from $26.4M) and a net loss of $64.8M ($0.57/share) versus a $62.0M loss in 2024; cash and short-term investments totaled $54M at year-end. The company highlighted 107 active partners, 407 programs, 32 clinical programs/approved products and $3.0B of contracted milestone payments (portfolio average royalty ~3.4%). Management launched OmniUltra and the Exploration platform (two Exploration systems deployed) and issued 2026 guidance of $25M–$30M revenue, $80M–$85M operating expense (cash operating expense $50M–$55M) and year-end cash of $30M–$35M. These results show near-term revenue weakness but provide visibility from large contracted milestones and platform rollouts that underpin management's cautious trajectory toward cash-flow positivity.

Analysis

The company is transitioning from an episodic, milestone-driven cash profile toward a diversified mix that can generate annuity-like revenue if instrument placements scale and consumables pull-through proves sticky. In practice that means the valuation premium should accrue not from near-term milestone timing but from durable gross margins on recurring consumables + subscription services; every incremental installed instrument that retains a 2–3 year consumables cadence compounds long-term free cash flow far more predictably than a single milestone.

Strategically, the emergence of a discovery capability that yields much smaller binding units creates optionality across multispecifics, radiopharma, and peptide adjacencies — markets with different licensing norms and often higher downstream royalty leverage. That adjacency effect increases the addressable partner set (and monetizable endpoints) but also invites competitive responses: large pharmas could either accelerate co-development (lifting near-term milestones) or vertically integrate discovery to avoid long-term royalty drag, producing asymmetric outcomes for licensor economics.

Key risks are cadence and concentration: commercial traction for capital instruments is governed by capital-budget cycles and implementation timelines (quarters to years), and clinical readouts remain binary catalysts that can swing milestone flows. Operationally, margin capture depends on supply-chain control for single-use consumables and the company’s ability to maintain pricing power as partners scale. Time horizons: expect most valuation re-rating drivers to play out over 6–24 months, royalties accruing thereafter.

Contrarian view: market attention on current P&L lumpiness understates option value of platform diversification and recurring revenue pathways; conversely, if instrument adoption stalls or partners negotiate away upside for upfront access, much of that optionality will be delayed or discounted. Express exposure via event- and structure-aware trades rather than outright cash positions.

Key Decisions for Investors

• Directional/options sleeve (12–18 months): Establish a defined-cost bullish position in OABIW using a calendar or vertical call spread to capture multiple partner clinical readouts and early instrument adoption while capping premium. Target a notional size that limits downside to a 1–2% portfolio hit; upside is asymmetric if 1–2 high-visibility partner events hit and instrument momentum accelerates.
• Pair trade to de-risk sponsor-binary risk (6–12 months): Go long OABIW (platform exposure) and short TEVA (sponsor execution exposure) to isolate platform optionality from single-sponsor trial binary. Use equal notional sizing and trim both legs on early readouts; this has favorable risk/reward if platform cashflows decouple from any single partner outcome.
• Accumulate on weakness via cash-secured puts (6 months): Sell modest-sized cash-secured puts on OABIW at a strike ~10–15% below current levels to build position at a lower basis if trials/milestones slip. If assigned, convert to a long-term core holding; if not, collect premium to improve entry economics.
• Event-driven partner exposure (short-term calls, 3–9 months): Buy near-dated calls on selective partners (e.g., IMVT-equivalent exposures) with upcoming readouts where success would trigger visible milestone uplifts for the platform. Keep position sizes small due to binary downside; expect 3:1+ payoff on successful data and total loss on failures.